Immune checkpoint inhibitors (ICIs) are essential for urothelial carcinoma (UC) treatment. Fibroblast growth factor receptor (FGFR) alterations. as common oncogenic drivers in UC. have been reported to drive T cell depletion of UC immune microenvironment via up-regulating FGFR signaling. https://www.spidertattooz.com/Venture-Pouch/